{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:43:36Z","timestamp":1792608216676,"version":"4.5.0"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Lung involvement is a distinctive feature of antisynthetase syndrome (ASS) and it is considered a basic disease-classifying criterion. In this review, we go over clinical features, radiological patterns, prognostic factors, pathogenesis and treatment of lung involvement in ASS patients, focusing on the clinical differences linked to the different antibody specificities known so far.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The lung is the most common extramuscular organ involved in ASS and has the greatest impact on patient prognosis. The pulmonary disease-defining manifestation in ASS is interstitial lung disease (ILD), yet a proportion of patients also develop pulmonary arterial hypertension and, less frequently, obstructive bronchiolitis or acute respiratory failure according to drivers not yet fully understood but likely associated with the underlying autoantibody pattern. Clinical presentation of pulmonary involvement can range from milder forms to a rapidly progressive disease which may lead to chronic lung damage if misdiagnosed and not properly treated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The knowledge of risk factors associated with progressive or refractory lung damage is important to identify and properly treat patients with the poorest prognosis. For those with a disease not responsive to conventional therapy the efficacy of other therapeutic option is under evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000663","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T07:48:51Z","timestamp":1568101731000},"page":"603-610","source":"Crossref","is-referenced-by-count":53,"title":["Pulmonary involvement in antisynthetase syndrome"],"prefix":"10.1097","volume":"31","author":[{"given":"Michela","family":"Gasparotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Saccon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ghirardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Iaccarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/BOR.0000000000000548","article-title":"New insights in myositis-specific autoantibodies","volume":"30","author":"Ghirardello","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00408-014-9665-7","article-title":"Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies","volume":"193","author":"Tomonaga","year":"2015","journal-title":"Lung"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"(Suppl 10)","key":"R9-20230828","article-title":"Antisynthetase syndrome: prevalence of serositis in autoantibody subsets [abstract]","volume":"70","author":"Katz","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2169\/internalmedicine.0302-17","article-title":"Anti-PL-7 antisynthetase syndrome with eosinophilic pleural effusion","volume":"57","author":"Saito","year":"2018","journal-title":"Intern Med"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.rmed.2014.09.003","article-title":"Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type","volume":"108","author":"Johnson","year":"2014","journal-title":"Respir Med"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.150966","article-title":"A multidisciplinary evaluation helps identify the antisynthetase syndrome in patients presenting as idiopathic interstitial pneumonia","volume":"43","author":"Chartrand","year":"2016","journal-title":"J Rheumatol"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000488358","article-title":"Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies","volume":"96","author":"Yamakawa","year":"2018","journal-title":"Respiration"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the antisynthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"e023998","DOI":"10.1136\/bmjopen-2018-023998","article-title":"Systematic review and meta-analysis of prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"8","author":"Kamiya","year":"2018","journal-title":"BMJ Open"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.111604","article-title":"Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use","volume":"39","author":"Stanciu","year":"2012","journal-title":"J Rheumatol"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome: ILD in anti-Jo-1 patients","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0000000000000434","article-title":"Clinical spectrum of anti-Jo-1-associated disease","volume":"29","author":"Monti","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"R23-20230828","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in antisynthetase syndrome","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur J Radiol"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0970-2113.173055","article-title":"Antisynthetase syndrome: an under-recognized cause of interstitial lung disease","volume":"33","author":"Maturu","year":"2016","journal-title":"Lung India"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in antisynthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","article-title":"The long-term outcome of interstitial lung disease with antiaminoacyl-tRNA synthetase antibodies","volume":"127","author":"Tanizawa","year":"2017","journal-title":"Respir Med"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3899\/jrheum.151067","article-title":"Pulmonary involvement in the antisynthetase syndrome: a comparative cross-sectional study","volume":"43","author":"Andersson","year":"2016","journal-title":"J Rheumatol"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rmed.2016.12.014","article-title":"Interstitial lung disease and myositis-specific and associated autoantibodies: clinical manifestations, survival and the performance of the new ATS\/ERS criteria for interstitial pneumonia with autoimmune features (IPAF)","volume":"123","author":"Mej\u00eda","year":"2017","journal-title":"Respir Med"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1183\/09031936.00104310","article-title":"Antisynthetase syndrome positive for antithreonyl-tRNA synthetase (anti-PL7) antibodies","volume":"37","author":"Hervier","year":"2011","journal-title":"Eur Respir J"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur J Intern Med"},{"key":"R33-20230828","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.humpath.2014.01.018","article-title":"The pulmonary histopathologic manifestations of the anti-PL7\/antithreonyl transfer RNA synthetase syndrome","volume":"45","author":"Yousem","year":"2014","journal-title":"Hum Pathol"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5858\/arpa.2013-0667-OA","article-title":"The pulmonary histopathology of anti-KS transfer RNA synthetase syndrome","volume":"139","author":"Schneider","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jclinpath-2014-202367","article-title":"Pulmonary pathologic manifestations of antiglycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy","volume":"67","author":"Schneider","year":"2014","journal-title":"J Clin Pathol"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s10067-016-3258-1","article-title":"Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ antisynthetase syndrome: a case series","volume":"35","author":"Giannini","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R37-20230828","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R38-20230828","first-page":"76","article-title":"Acute respiratory failure as the first manifestation of antisynthetase syndrome","volume":"16","author":"Toujani","year":"2017","journal-title":"Tanaffos"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.resinv.2016.01.005","article-title":"Severe respiratory failure as a presenting feature of an interstitial lung disease associated with antisynthetase syndrome (ASS)","volume":"54","author":"Piroddi","year":"2016","journal-title":"Respir Investig"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4046\/trd.2016.79.3.188","article-title":"Acute respiratory distress syndrome as the initial clinical manifestation of an antisynthetase syndrome","volume":"79","author":"Kim","year":"2016","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/thx.2006.069237","article-title":"Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset","volume":"63","author":"Tillie-Leblond","year":"2008","journal-title":"Thorax"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00124743-199908000-00008","article-title":"Bronchiolitis obliterans with organizing pneumonia (BOOP) heralding anti-Jo-1-positive polymyositis","volume":"5","author":"Xing","year":"1999","journal-title":"J Clin Rheumatol"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/cdli.4.2.236-240.1997","article-title":"Inflammatory myopathy, bronchiolitis obliterans\/organizing pneumonia, and anti-Jo-1 antibodies \u2013 an interesting association","volume":"4","author":"Kalenian","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/ajrccm\/141.3.727","article-title":"Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings","volume":"14","author":"Tazelaar","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Care Res"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/ar3347","article-title":"The lung as a possible target for the immune reaction in myositis","volume":"13","author":"Danoff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20020186","article-title":"Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells","volume":"196","author":"Howard","year":"2002","journal-title":"J Exp Med"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/rheumatology\/ket003","article-title":"Involvement of antigen-driven mechanisms in interstitial pneumonia with polymyositis","volume":"52","author":"Fukushima","year":"2013","journal-title":"Rheumatology"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.4049\/jimmunol.1501902","article-title":"Involvement of NK cells and NKp30 pathway in antisynthetase syndrome","volume":"197","author":"Hervier","year":"2016","journal-title":"J Immunol"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52\/anti-Ro 60 autoantibodies","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sj\u00f6gren's syndrome: a possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1445-5994.2010.02164.x","article-title":"Clinical heterogeneity and prognostic features of South Australian patients with antisynthetase autoantibodies: antisynthetase syndrome","volume":"41","author":"Dugar","year":"2011","journal-title":"Intern Med J"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/art.40679","article-title":"Interstitial pneumonia with autoimmune features: an emerging challenge at the intersection of rheumatology and pulmonology","volume":"70","author":"Wilfong","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulm Med"},{"key":"R58-20230828","first-page":"609","article-title":"Clinical characteristics of Japanese patients with anti-PL-7 (antithreonyl-tRNA synthetase) autoantibodies","volume":"23","author":"Sato","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MD.0b013e318260977c","article-title":"Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European Multicenter Study (EUMYONET) and review of the literature","volume":"91","author":"Labirua-Iturburu","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with antiaminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"key":"R61-20230828","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel435","article-title":"Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies","volume":"46","author":"Hirakata","year":"2007","journal-title":"Rheumatology"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/his.12420","article-title":"Expanding the spectrum of pulmonary histopathological manifestations of antisynthetase syndrome: anti-EJ-associated acute fibrinous and organizing pneumonia","volume":"65","author":"Sauter","year":"2014","journal-title":"Histopathology"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12890-016-0325-y","article-title":"Long-term clinical course of antiglycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy","volume":"16","author":"Sasano","year":"2016","journal-title":"BMC Pulm Med"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2169\/internalmedicine.48.2207","article-title":"Nonspecific interstitial pneumonia (NSIP) associated with anti-KS antibody: differentiation from idiopathic NSIP","volume":"48","author":"Okayasu","year":"2009","journal-title":"Intern Med"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08916930600622645","article-title":"Clinical implications of autoantibody screening in patients with autoimmune myositis","volume":"39","author":"Ghirardello","year":"2006","journal-title":"Autoimmunity"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS \u2013 a autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R68-20230828","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","article-title":"Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy","volume":"109","author":"Rutjes","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"R69-20230828","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R71-20230828","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/joim.12511","article-title":"Update on the pharmacological treatment of adult myositis","volume":"280","author":"Oddis","year":"2016","journal-title":"J Intern Med"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0961203314554849","article-title":"The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"24","author":"Kurita","year":"2014","journal-title":"Lupus"},{"issue":"(Suppl 10)","key":"R74-20230828","article-title":"Calcineurin inhibitor for the treatment of myositis-associated interstitial lung disease: comparison between cyclosporine and tacrolimus [abstract]","volume":"70","author":"Gono","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R75-20230828","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R76-20230828","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.rmed.2012.01.001","article-title":"Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome","volume":"106","author":"Marie","year":"2012","journal-title":"Respir Med"},{"key":"R77-20230828","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"key":"R78-20230828","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in antisynthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"key":"R79-20230828","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3899\/jrheum.170541","article-title":"Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review","volume":"45","author":"Doyle","year":"2018","journal-title":"J Rheumatol"},{"key":"R80-20230828","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12026-013-8408-9","article-title":"Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature","volume":"56","author":"Nalotto","year":"2013","journal-title":"Immunol Res"},{"key":"R81-20230828","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"key":"R82-20230828","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"key":"R83-20230828","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCRESAHA.115.303827","article-title":"Current clinical management of pulmonary arterial hypertension","volume":"115","author":"Zamanian","year":"2014","journal-title":"Circ Res"},{"key":"R84-20230828","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2010.08.004","article-title":"Pulmonary hypertension in systemic sclerosis","volume":"41","author":"Chatterjee","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R85-20230828","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00296-012-2659-y","article-title":"Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis","volume":"33","author":"Shahane","year":"2013","journal-title":"Rheumatol Int"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T02:01:50Z","timestamp":1693188110000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000663","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}